Ceftaroline Fosamil (Teflaro) - A New IV Cephalosporin
The FDA has approved ceftaroline fosamil (Teflaro –
Forest), an intravenous (IV) cephalosporin, for treatment
of acute bacterial skin and skin structure infections,
including those caused by methicillin-resistant
Staphylococcus aureus (MRSA), and for treatment of
community-acquired bacterial pneumonia in adults. It
is the first beta-lactam antibiotic approved for treatment
of MRSA....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Ceftaroline Fosamil (Teflaro) - A New IV Cephalosporin
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1356
Article Code: 1356a
Date: January 24, 2011
Volume: 53
Pages: 5-6
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1356
Article Code: 1356a
Date: January 24, 2011
Volume: 53
Pages: 5-6
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)
